Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs

Aug 24, 2020•almost 5 years ago

Amount Raised

$115 Million

Round Type

series c

San DiegoBiopharmaTherapeuticsBiotechnology

Description

Connect Biopharma ("Connect"), a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules, today announced the completion of a $115 million Series C financing led by new investor RA Capital Management. Additional new investors Lilly Asia Ventures, Boxer Capital, and HBM Healthcare Investments joined existing investor Qiming Venture Partners in the financing. The company also announced that, in conjunction with the financing, Derek DiRocco, PhD, Principal at RA Capital Management, is joining the Connect Biopharma Board of Directors.

Company Information

Company

Cbp 201

Location

San Diego, California, United States

About

Connect Biopharma is a global, clinical-stage biopharmaceutical company applying its expertise in T cell biology and deep knowledge of the drug discovery industry to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech